Volume 18, Number 7—July 2012
Dispatch
Seroconversion to Seasonal Influenza Viruses after A(H1N1)pdm09 Virus Infection, Quebec, Canada
Mariana Baz, Jesse Papenburg, Marie-Eve Hamelin, Manale Ouakki, Danuta M. Skowronski, Gaston De Serres, and Guy Boivin
Table
Clinical features and microneutralization antibody titers against influenza A(H1N1)pdm09 and seasonal influenza A viruses of persons who seroconverted to >2 influenza viruses, Quebec City, Quebec, Canada, 2009*
| Participant no./age, y | RT-PCR for A(H1N1) pdm09 | Titers, acute phase/convalescent phase (-fold increase) |
||||||
|---|---|---|---|---|---|---|---|---|
| Symptoms |
A/Quebec/147023/ 2009; A(H1N1)pdm09 | A/Brisbane/59/ 2007 (H1N1) | A/New Caledonia/ 99 (H1N1) | A/Panama/2007/99 (H3N2) | ||||
| ARI | ILI | |||||||
| 39A/7 | + | + | + | <10/160 (16) | <10/320 (32) | <10/160 (16) | 320/160 (0) | |
| 39C/11 | + | + | + | <10/40 (4) | 10/160 (16) | <10/40 (4) | 2,560/2,560 (0) | |
| 49A/28 | + | + | + | <10/160 (16) | 40/160 (4) | <10/20 (2) | 320/320 (0) | |
| 49B/23 | + | + | + | <10/640 (64) | <10/160 (16) | 40/160 (4) | 40/40 (0) | |
| 55F/7 | + | + | + | <10/40 (4) | 10/40 (4) | 20/80 (4) | 10/10 (0) | |
| 16C/7 | + | + | + | <10/80 (8) | 160/320 (2) | 40/160 (4) | 80/80 (0) | |
| 56A/12 | + | + | + | <10/40 (4) | 80/320 (4) | 40/80 (2) | 2,560/2,560 (0) | |
| 65B/40 | + | + | + | <10/320 (32) | <10/20 (2) | 10/40 (4) | 320/320 (0) | |
| 03E/17 | + | + | + | <10/80 (8) | 40/80 (2) | 160/160 (0) | 640/5120 (8) | |
| 10B/14 | + | + | + | <10/80 (8) | 20/20 (0) | 80/320 (4) | 640/640 (0) | |
| 11C/61† | + | + | + | <10/1,280 (128) | 40/160 (4) | 160/160 (0) | 320/1,280 (4) | |
| 44B/9 | + | + | + | <10/<80 (8) | 1,280/640 (0) | 1,280/1,280 (0) | 160/640 (4) | |
| 44C/44 | – | + | – | <10/20 (2) | 10/80 (8) | 80/80 (0) | 160/640 (4) | |
| 58A/13 | + | + | + | <10/80 (8) | <10/20 (2) | 10/20 (2) | 1,280/5,120 (4) | |
| 58B/43 | + | + | – | <10/160 (16) | <10/10 (0) | <10/<10 (0) | 20/160 (8) | |
*RT-PCR, reverse transcription PCR; ARI, acute respiratory illness (i.e., presence of ≥2 of the following signs/symptoms: fever [≥37.8°C] or feverishness, cough, sore throat, or rhinorrhea); ILI, influenza-like illness (i.e., fever and cough and/or sore throat); +, positive; –, negative.
†Received seasonal vaccine in 2008–09.
Page created: June 13, 2012
Page updated: June 13, 2012
Page reviewed: June 13, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.